Table 4.
Antihypertensive medication use for another indication during pregnancy and risk of SGA, National Birth Defects Prevention Study, 1997-2011. The reference group for all logistic regression models is normotensive women who did not report taking an antihypertensive medication during pregnancy. Values for SGA and Non-SGA columns are n (%).
| Exposure group | SGA (n=932) |
Non-SGA (n=9,161) |
OR (95% CI)a | AOR (95% CI)b |
|---|---|---|---|---|
| Any antihypertensive medication | 9 (0.97) | 39 (0.43) | 2.28 (1.10, 4.72) | 2.19 (0.99, 4.82) |
| β-blocker | 5 (0.54) | 13 (0.14) | 3.81 (1.35, 10.69) | 3.81 (1.20, 12.14) |
| Calcium channel blocker | 3 (0.32) | 18 (0.20) | 1.65 (0.48, 5.60) | - |
| Diuretic | 0 (0) | 6 (0.07) | - | - |
| α-blocker | 1 (0.11) | 1 (0.01) | - | - |
| Direct vasodilator | 0 (0) | 1 (0.01) | - | - |
| No hypertension (reference) | 923 (99.0) | 9,122 (99.6) | 1.00 | 1.00 |
a
For groups with <5 exposed SGA births, we calculated the exact 95% CI.
b
Adjusted for maternal race/ethnicity, maternal age at delivery, maternal prepregnancy BMI, late pregnancy smoking, early pregnancy folic acid supplement use, and study site.